ChromaDex Corporation (CDXC)
| Market Cap | 529.19M |
| Revenue (ttm) | 59.60M |
| Net Income (ttm) | -21.40M |
| Shares Out | 64.16M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $7.53 |
| Previous Close | $8.58 |
| Change ($) | -1.05 |
| Change (%) | -12.24% |
| Day's Open | 7.78 |
| Day's Range | 7.50 - 8.26 |
| Day's Volume | 1,302,865 |
| 52-Week Range | 3.82 - 23.66 |
ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -10.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported first quarter 2021 financial results. First Quarter 2021 and Recent Highlights Total net sales of $14.7 mil...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology compan...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 6, 2021 at 4:30 p.m. ET to discuss its financial results for ...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a strategic supply agreement with Health & Happiness (H&H) Group, a global leader in p...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #management--ChromaDex Corp. (NASDAQ:CDXC) announced today that it has appointed Fadi Karam as Chief Marketing Officer. Karam has spent his career driving consumer...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #collaboration--ChromaDex Corp. (NASDAQ: CDXC) today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen® ni...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenti...
Investors need to pay close attention to ChromaDex (CDXC) stock based on the movements in the options market lately.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenti...
Another investment bank lifts its price target on the company's stock.
ChromaDex (CDXC) delivered earnings and revenue surprises of 9.09% and 0.31%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of ChromaDex (NASDAQ:CDXC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 9.09% over the past year to ($0.10), which missed the e...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Earnings--ChromaDex Corp. (NASDAQ:CDXC) today reported fourth quarter and full year 2020 financial results. Fourth Quarter 2020 and Recent Highlights Total net sa...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #healthyaging--ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product and industry-leading NAD+ booster Tru Niagen® will be available in 3,000...
On Wednesday, March 10, ChromaDex (NASDAQ:CDXC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #HealthyAging--ChromaDex Corp. (NASDAQ: CDXC) is scheduled to participate in a virtual presentation at the Oppenheimer 31st Annual Healthcare Conference on Wednesd...
ChromaDex (CDXC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today it has appointed David L. Katz, MD, MPH, FACPM, FACP, FACLM - CEO of Diet ID, Inc, founder and forme...
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chromadex Corp (NASDAQ: CDXC) shares jumped 111% in the regular and after-hours sessions today. What Happened: The price movement on Thursday was accompanied by intense trading with volumes of 116.67 mi...
Promising Phase III clinical results for Covid-19 treatment have investors falling over themselves to buy into ChromaDex stock. The post CDXC Stock: Why ChromaDex Shares Are Rocketing Higher Today appea...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #COVID19research--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COV...
ChromaDex Corp (NASDAQ: CDXC) enters into a securities purchase agreement to sell $25 million in common stock via a private placement led by a new international investor. The company will sell around 3....
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) announced today that it has entered into a securities purchase agreement for the sale of $25.0 million of its commo...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., March 10, 2021 at 4:30 p.m. ET to discuss its financial resul...
ChromaDex was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or ...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Cofactor Supplementation Reduces Liver Fat in Nonalcohol...
ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a human clinical trial of Niagen® (nicotinamide riboside, or NR) investigating its...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced today the exclusive launch of its TRU NIAGEN® EX Stick Packs with Watsons Hong Kong, available online and ...
Tru Niagen, CDXC's patented product, shows strong promise in billion dollar markets. Market underestimates monopoly length by ~3x.
ChromaDex's (CDXC) CEO Rob Fried on Q3 2020 Results - Earnings Call Transcript
ChromaDex (CDXC) delivered earnings and revenue surprises of 36.36% and -0.81%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (Nasdaq:CDXC) today reported third quarter financial results. 2020 Third Quarter and Recent Highlights Total net sales of $14.2 mi...
On Wednesday, November 04, ChromaDex (NASDAQ: CDXC) will release its latest earnings report. Check out Benzinga's preview to understand the implications.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., November 4, 2020 at 4:30 p.m. ET to discuss its financial res...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study published in The European Molecular Biology Organization Journal looking at the effect...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced its flagship ingredient, Tru Niagen®, is now available in Nestlé Health Science’s new Celltrient™ Ce...
ChromaDex: Blazing Ahead Of Ponce De Leon
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor inf...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementation accelerates recovery in mil...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced new preclinical research published in Investigative Ophthalmology & Visual Science finding Niagen® (...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presen...
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today announced the 11th published human trial on its patented NAD-boosting nutrient Niagen®, further highlighting i...
ChromaDex Corporation (CDXC) CEO Rob Fried on Q2 2020 Results - Earnings Call Transcript
ChromaDex (CDXC) delivered earnings and revenue surprises of 45.45% and 12.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About CDXC
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of... [Read more...]
| Industry Biotechnology | |
| CEO Robert Fried | Employees 110 |
| Stock Exchange NASDAQ | Ticker Symbol CDXC |
Financial Performance
In 2020, ChromaDex's revenue was $59.26 million, an increase of 28.01% compared to the previous year's $46.29 million. Losses were -$19.93 million, -38.02% less than in 2019.
Analyst Forecasts
According to 6 analysts, the average rating for ChromaDex stock is "Strong Buy." The 12-month stock price forecast is 16.00, which is an increase of 112.48% from the latest price.